Shares of biotech company Eikon Therapeutics (NYSE:EIKN) jumped 6% to $14.65 on Monday after at least five Wall Street brokerages began coverage with bullish ratings once the IPO research quiet period concluded. One notable outlier, Wedbush, published a negative rating on February 26.
Analysts from J.P. Morgan characterized Eikon's asset mix as strategically arranged, noting the firm has two advanced assets acquired through in-licenses and a broader pipeline generated by its super resolution microscopy discovery engine. J.P. Morgan also pointed to the company's leadership, which includes Roger Perlmutter, a former Merck executive, and other former Merck personnel who participated in the development of Keytruda.
The company's lead candidate, EIK1001, is undergoing testing in combination with Keytruda in a mid- to late-stage trial targeting a type of skin cancer. Morgan Stanley reported phase 2 results for EIK1001 administered with Keytruda and chemotherapy in first-line non-small cell lung cancer showing a 60% objective response rate overall - with a 71% response in squamous cases and 56% in non-squamous cases.
BofA Securities emphasized Eikon's discovery platform, describing it as a proprietary, high-resolution microscope capable of visualizing proteins inside living cells. The bank noted that the technology can produce drug candidates for either internal development or potential out-licensing arrangements.
Morgan Stanley also highlighted Eikon's PARP1-selective programs, specifically EIK1003 and EIK1004. According to Morgan Stanley, EIK1003 demonstrated monotherapy activity in heavily pretreated breast and ovarian cancer patients, including a 31% objective response rate in PARP-na ve patients.
Another program cited by Morgan Stanley is EIK1005, a Werner syndrome helicase inhibitor that the firm said progressed from a research tool to a clinical-stage candidate in under 18 months and has entered Phase 1/2 trials.
Eikon completed its initial public offering in New York last month, selling 21.2 million shares at $18 apiece. The underwriting syndicate for the offering included J.P. Morgan, Morgan Stanley, BofA Securities, Cantor, and Mizuho.
Context and market reaction
The wave of analyst initiations following the IPO quiet period corresponded with the stock's intraday increase. While multiple firms issued favorable coverage focused on the company's platform and clinical progress, the presence of at least one negative rating underscores divergent views among brokerage research teams.
What remains unchanged in the public record
- The company price moved to $14.65 on Monday, reflecting a 6% gain.
- Analysts from J.P. Morgan, Morgan Stanley, and BofA Securities provided supportive commentary on technology and pipeline elements.
- Wedbush issued a negative rating on February 26.
- Eikon sold 21.2 million IPO shares at $18 each; the listed underwriters participated in the offering.